Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
Federal Reserve Vice Chair Richard Clarida said Friday that the global economy has deteriorated in the past month.Marketsread more
The latest escalation in the trade war ups the odds the economy will fall into recession and that the Fed will aggressively cut rates.Market Insiderread more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
"We don't need China and, frankly, would be far better off without them," Trump tweeted.Politicsread more
"My only question is, who is our bigger enemy, Jay Powell or Chairman Xi?" Trump wrote amid a series of tweets that rattled markets Friday.Politicsread more
"I would love this to be clarified. We come to a deal on trade, boy, this market is up 10 to 15%, but without it's going to be worrisome," Jeremy Siegel says.Marketsread more
The final week of August could be highly volatile as markets fret over the economy and the latest developments in trade wars.Market Insiderread more
Tesla solar energy systems reportedly ignited at an Amazon warehouse in Redlands, California last June, and the Seattle e-commerce titan confirmed that it has no further plans...Technologyread more
The death comes as federal and state health officials investigate a slew of lung illnesses in connection to e-cigarette use.Health and Scienceread more
The Senate Aging Committee has asked pharmaceutical giant Pfizer for information about soaring prices for the generic drug naloxone, used to reverse the effects of an opioid overdose.
The drug's price rose from $45 for a set of 10 vials in 2009 to $263.88 in early 2014—an increase of almost 600 percent, before settling to $189.96, CNBC reported in September.
"Drug overdoses are now the leading cause of accidental death in the United States, many related to misuse or abuse of prescription opioids," Senators Susan Collins and Claire McCaskill wrote in a letter to Pfizer CEO Ian Read dated Nov. 28, a copy of which was obtained by CNBC.
Pfizer gained naloxone when it acquired Hospira for $17 billion in 2015. The senators said they'd already received 2015-2016 pricing information on the drug from Pfizer, in response to an earlier letter.
"Explain, in detail, the number and amount of price increases and decreases taken by Hospira between 2009 and 2014 for naloxone," the senators wrote.
They also asked for details on how Hospira came to the decision to raise the price, as well as how much the increases contributed to research and development into improving the product, and whether any issues of patient access arose.
In response to an inquiry from CNBC, Pfizer defended its pricing, saying the drug's cost was "priced responsibly" in a statement.
"From the time Naloxone entered our portfolio...our focus has been on providing access to this life saving treatment and we believe it is priced responsibly at a wholesale acquisition cost (WAC) price of $15.83 per dose for the single dose vial, and $11.87 per dose for the multidose vial (10 doses in a vial)," the statement read.
"Pfizer's Naloxone Access Program includes a donation of up to 1 million doses of Naloxone over four years and $1 million in opioid overdose grants to several states."
Pfizer isn't the only maker of naloxone. Other formulations and delivery systems are on the market, including an auto injector called Evzio from private manufacturer Kaleo that costs almost $4,000 for two doses.
Collins and McCaskill wrote letters to five manufacturers in June inquiring about price increases.